We used Cistrome Cancer to analyze data from The Cancer Genome atlas (TCGA) and showed that both in GBM as well as low grade gliomas (LGGs), patients with higher EZH2 expression have a worse prognosis in comparison to patients with lower EZH2 expression (Figures 1D, E). Here, EZH2 is linked to central nervous system cancer.